An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
Clinical trial NCT05131438 · NO_LONGER_AVAILABLE
Trial details
- NCT number
- NCT05131438
- Sponsor
- EQRx International, Inc.
- Status
- NO_LONGER_AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.